39,381 Shares in Boston Scientific Co. (NYSE:BSX) Acquired by Gilliland Jeter Wealth Management LLC

Gilliland Jeter Wealth Management LLC bought a new stake in Boston Scientific Co. (NYSE:BSX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 39,381 shares of the medical equipment provider’s stock, valued at approximately $2,277,000.

Several other hedge funds have also bought and sold shares of the stock. Bruce G. Allen Investments LLC purchased a new stake in shares of Boston Scientific during the 4th quarter valued at $28,000. Venturi Wealth Management LLC increased its stake in Boston Scientific by 58.0% in the fourth quarter. Venturi Wealth Management LLC now owns 586 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 215 shares during the last quarter. Motco raised its position in Boston Scientific by 136.3% during the third quarter. Motco now owns 645 shares of the medical equipment provider’s stock valued at $34,000 after purchasing an additional 372 shares in the last quarter. Cetera Trust Company N.A bought a new stake in Boston Scientific during the fourth quarter worth about $43,000. Finally, Asset Dedication LLC boosted its holdings in shares of Boston Scientific by 42.6% in the 3rd quarter. Asset Dedication LLC now owns 786 shares of the medical equipment provider’s stock worth $41,000 after purchasing an additional 235 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Down 0.1 %

Shares of NYSE:BSX traded down $0.09 during midday trading on Friday, reaching $73.17. The company’s stock had a trading volume of 8,786,294 shares, compared to its average volume of 6,225,924. Boston Scientific Co. has a 12-month low of $48.35 and a 12-month high of $74.39. The firm has a market capitalization of $107.35 billion, a P/E ratio of 61.49, a PEG ratio of 2.51 and a beta of 0.78. The firm has a 50 day moving average of $67.82 and a 200-day moving average of $60.56. The company has a quick ratio of 0.82, a current ratio of 1.32 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of $0.51 by $0.04. Boston Scientific had a net margin of 12.06% and a return on equity of 16.63%. The business had revenue of $3.73 billion for the quarter, compared to analysts’ expectations of $3.59 billion. During the same quarter in the prior year, the company earned $0.45 earnings per share. On average, research analysts anticipate that Boston Scientific Co. will post 2.32 earnings per share for the current year.

Insider Buying and Selling

In other Boston Scientific news, Director Edward J. Ludwig sold 7,000 shares of Boston Scientific stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total value of $455,210.00. Following the completion of the transaction, the director now directly owns 41,374 shares of the company’s stock, valued at $2,690,551.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, EVP John Bradley Sorenson sold 16,351 shares of Boston Scientific stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $69.30, for a total value of $1,133,124.30. Following the completion of the sale, the executive vice president now directly owns 50,638 shares in the company, valued at approximately $3,509,213.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Edward J. Ludwig sold 7,000 shares of the company’s stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $65.03, for a total transaction of $455,210.00. Following the transaction, the director now owns 41,374 shares in the company, valued at approximately $2,690,551.22. The disclosure for this sale can be found here. Insiders have sold a total of 50,979 shares of company stock worth $3,418,529 in the last quarter. Corporate insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on BSX. Argus boosted their target price on Boston Scientific from $69.00 to $80.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Evercore ISI boosted their price objective on shares of Boston Scientific from $72.00 to $78.00 and gave the stock an “outperform” rating in a report on Thursday. Barclays increased their target price on shares of Boston Scientific from $70.00 to $78.00 and gave the company an “overweight” rating in a report on Friday. Robert W. Baird boosted their price target on shares of Boston Scientific from $79.00 to $84.00 and gave the stock an “outperform” rating in a research note on Thursday. Finally, StockNews.com lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 16th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $75.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.